Genedata Bioprocess Licensed to Pfizer Inc.
February 8, 2018
Genedata, a leading provider of advanced software solutions for biopharma R&D, today announced that Pfizer Inc. has licensed the Genedata Bioprocess™ enterprise platform.
The integration of Genedata Bioprocess with Pfizer’s existing Genedata Biologics™ platform—in use since 2014—establishes a centralized data repository that can be accessed by both research and development units. Improving data tracking and analysis via integrated data collection and enhanced data association can potentially help streamline data-focused development.
"After conducting a pilot project to determine if Genedata Bioprocess had the potential to meet our requirements, we decided to move forward with its implementation,” said Dr. Sergio Rotstein, Director, Medicinal Sciences Business Technology, Pfizer.
“We are very pleased to see Pfizer adopting Genedata Bioprocess,” said Dr. Othmar Pfannes, CEO of Genedata. “This validates our strategy of developing a fully integrated workflow management platform that facilitates seamless R to D handovers of development candidates, samples, and associated data. In addition, a shared platform across R&D leads to substantial efficiency gains and cost savings.”
Genedata Bioprocess is a first-in-class, off-the-shelf enterprise software solution that enables fully integrated workflow support for large-molecule development and CMC. It supports the development of more efficient manufacturing processes and can be operated in a stand-alone mode or fully integrated with Genedata Biologics, the market-leading workflow system for large-molecule discovery. Genedata Bioprocess is a modular system that supports the full process - from cell line development, upstream process development (USP), downstream process development (DSP) - to formulation and analytical development, as well as critical quality attribute assessment. The platform scales with highest data volumes and integrates directly with all relevant laboratory equipment, such as bioreactors and analytics devices. Genedata Bioprocess has been co-developed with major biopharmaceutical companies over the past five years.
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.